The landscape of NSCLC treatment has been revolutionized by the identification of specific oncogenic driver mutations, such as those in the Epidermal Growth Factor Receptor (EGFR) gene and Anaplastic Lymphoma Kinase (ALK) gene rearrangements. This evidence concerns the gene ALK and non-small cell lung carcinoma.